5) 坪内博仁, 他 : 免疫抑制剤・化学療法により発症するB型肝炎対策. 肝臓, 50 : 38-42, 2009
6) Pmda 報告いただいた副作用報告に関する情報
7) 「B型肝炎ウイルス感染リウマチ性疾患患者への免疫抑制療法に関する提言」 (日本リウマチ学会/編), 2014
8) Jensen PA, et al : Guidelines for preventing the transmission of Mycobacterium tuberculosis in health-care settings, 2005. MMWR Recomm Rep, 54 : 1-141, 2005
8) Singh JA, et al : 2015 American College of Rheumatology Guideline for the Treatment of Rheumatoid Arthritis. Arthritis Rheumatol, 68 : 1-26, 2016
9) 「関節リウマチ治療におけるメトトレキサート (MTX) 診療ガイドライン 2016年改訂版」(日本リウマチ学会MTX 診療ガイドライン策定小委員会/編), 羊土社, 2016
10) 「関節リウマチ (RA) に対する TNF 阻害薬使用の手引き (2020.2改訂版) 」 (日本リウマチ学会, 他/編) https://www.ryumachi-jp.com/info/guideline_tnf.pdf
11) 「関節リウマチ (RA) に対するIL-6阻害薬使用の手引き (2020.2改訂版) 」 (日本リウマチ学会, 他/編) https://www.ryumachi-jp.com/info/guideline_IL-6.pdf
12) 「関節リウマチ (RA) に対するアバタセプト使用の手引き (2020.2改訂版) 」 (日本リウマチ学会, 他/編) https://www.ryumachi-jp.com/info/guideline_abt.pdf
13) 「全例市販後調査のためのペフィシチニブ使用ガイドライン」 (日本リウマチ学会, 他/編) https://www.ryumachi-jp.com/info/guideline_peficitinib.pdf
14) 「全例市販後調査のためのバリシチニブ適正使用ガイド (2020.2改訂版) 」 (日本リウマチ学会, 他/編) https://www.ryumachi-jp.com/info/guideline_barishichinibu.pdf
15) 「全例市販後調査のためのトファシチニブ適正使用ガイド (2020.2改訂版) 」 (日本リウマチ学会, 他/編) https://www.ryumachi-jp.com/info/guideline_tofacitinib.pdf
16) Till JE, et al : Finding Canadian cancer clinical trials on the Internet : an exploratory evaluation of online resources. CMAJ, 168 : 1127-1129, 2003
17) American Thoracic Society (ATS) and the Centers for Disease Control and Prevention (CDC) : Targeted tuberculin testing and treatment of latent tuberculosis infection. This official statement of the American Thoracic Society was adopted by the ATS Board of Directors, July 1999. This is a Joint Statement of the American Thoracic Society (ATS) and the Centers for Disease Control and Prevention (CDC). This statement was endorsed by the Council of the Infectious Diseases Society of America. (IDSA), September 1999, and the sections of this statement. Am J Respir Crit Care Med, 161 : S221-S247, 2000
19) Dheda K, et al : Tuberculosis. Lancet, 387 : 1211-1226, 2016
20) 日本結核病学会予防委員会・治療委員会 : 潜在性結核感染症治療指針. 結核, 88 : 497-512, 2013 https://www.kekkaku.gr.jp/pub/Vol.88(2013)/Vol88_No5/Vol88No5P497-512.pdf
21) Arkema EV, et al : Are patients with rheumatoid arthritis still at an increased risk of tuberculosis and what is the role of biological treatments? Ann Rheum Dis, 74 : 1212-1217, 2015
22) 「炎症性疾患に対する生物学的製剤と呼吸器疾患 診療の手引き 改訂第2版」 (日本呼吸器学会, 他/編), 2020
23) David M. Lewinsohn, et al : Official American Thoracic Society/Infectious Diseases Society of America/Centers for Disease Control and Prevention Clinical Practice Guidelines : Diagnosis of Tuberculosis in Adults and Children. CID, 64 : e1-e33, 2017 https://www.thoracic.org/statements/resources/tb-opi/diagnosis-of-tuberculosis-inadults-and-children.PDF
24) Pai M, et al : Systematic review : T-cell-based assays for the diagnosis of latent tuberculosis infection : an update. Ann Intern Med, 149 : 177-184, 2008
25) T-スポット(R). TB添付文書 (2017.1 改訂第8版) https://www.tspot-tb.jp/product/download/pdf/PI-TB-JP-V8.pdf
26) Anibarro L, et al : Interferon-γ release assays in tuberculosis contacts : is there a window period? Eur Respir J, 37 : 215-217, 2011
27) 「感染症法に基づく結核の接触者健康診断の手引き (改訂第5版) 」 (厚生労働科学研究 (新型インフルエンザ等新興・再興感染症研究事業)/編), 2014 https://jata.or.jp/rit/rj/2014.3sessyokusya1.pdf
28) 小橋吉博 : 抗結核薬に対する減感作療法について. 結核, 75 : 521-526, 2000 https://www.kekkaku.gr.jp/pub/Vol.88(2013)/Vol88_No5/Vol88No5P497-512.pdf
29) 2018 surveillance (exceptional review) of tuberculosis (NICE guideline NG33), 2018 https://www.nice.org.uk/guidance/ng33/resources/2018-surveillance-exceptionalreview-of-tuberculosis-nice-guideline-ng33-pdf-8546425319365
30) International Union Against Tuberculosis Committee on Prophylaxis : Efficacy of various durations of isoniazid preventive therapy for tuberculosis : five years of follow-up in the IUAT trial. International Union Against Tuberculosis Committee on Prophylaxis. Bull World Health Organ, 60 : 555-564, 1982
31) Finch CK, et al : Rifampin and rifabutin drug interactions : an update. Arch Intern Med, 162 : 985-992, 2002
32) 倉島篤行 : 7年ぶりに行われた肺非結核性抗酸菌症全国調査結果について. 結核, 90 (7) : 605-606, 2015
33) Daley CL, et al : Treatment of Nontuberculous Mycobacterial Pulmonary Disease : An Official ATS/ERS/ESCMID/IDSA Clinical Practice Guideline : Executive Summary. Clin Infect Dis : doi : 10.1093/cid/ciaa241, 2020
34) 日本結核病学会非結核性抗酸菌症対策委員会 : 肺非結核性抗酸菌症診断に関する指針-2008年. 結核, 83 (7) : 525-526, 2008 https://www.kekkaku.gr.jp/commit/ntm/200804sisin.pdf
35) Haworth CS & Floto RA : Introducing the new BTS Guideline : Management of non-tuberculous mycobacterial pulmonary disease (NTM-PD). Thorax, 72 : 969-970, 2017
36) Piersimoni C & Scarparo C : Pulmonary infections associated with non-tuberculous mycobacteria in immunocompetent patients. Lancet Infect Dis, 8 : 323-334, 2008
37) Kahana LM, et al : Mycobacterium avium complex infection in an immunocompetent young adult related to hot tub exposure. Chest, 111 : 242-245, 1997
38) 「Guidelines for the Prevention and Treatment of Opportunistic Infections in Adults and Adolescents with HIV」, AIDS info, 2020
39) Tomblyn M, et al : Guidelines for preventing infectious complications among hematopoietic cell transplantation recipients : a global perspective. Biol Blood Marrow Transplant, 15 : 1143-1238, 2009
40) Taplitz RA, et al : Antimicrobial Prophylaxis for Adult Patients With Cancer-Related Immunosuppression : ASCO and IDSA Clinical Practice Guideline Update. J Clin Oncol, 36 : 3043-3054, 2018
41) Fishman JA & Gans H : Pneumocystis jiroveci in solid organ transplantation : Guidelines from the American Society of Transplantation Infectious Diseases Community of Practice. Clin Transplant, 33 : e13587, 2019
42) 猪熊茂子, 他 : 免疫疾患に合併するニューモシスティス肺炎の予防規準. 「免疫疾患の合併症とその治療法に関する研究 平成16年度 総括研究報告書」 (橋本博史/総括), 厚生労働省, 2004
43) Thomas CF Jr & Limper AH : Pneumocystis pneumonia. N Engl J Med, 350 : 2487-2498, 2004
44) Kovacs JA & Masur H : Evolving health effects of Pneumocystis : one hundred years of progress in diagnosis and treatment. JAMA, 301 : 2578-2585, 2009
45) Green H, et al : Prophylaxis of Pneumocystis pneumonia in immunocompromised non-HIV-infected patients : systematic review and meta-analysis of randomized controlled trials. Mayo Clin Proc, 82 : 1052-1059, 2007
47) Godeau B, et al : Factors associated with Pneumocystis carinii pneumonia in Wegener's granulomatosis. Ann Rheum Dis, 54 : 991-994, 1995
48) Lertnawapan R, et al : Risk factors of Pneumocystis jeroveci pneumonia in patients with systemic lupus erythematosus. Rheumatol Int, 29 : 491-496, 2009
49) Landewe RB, et al : EULAR provisional recommendations for the management of rheumatic and musculoskeletal diseases in the context of SARS-CoV-2. Ann Rheum Dis, 79 : 851-858, 2020
50) Ito S & Koren G : Estimation of fetal risk from aerosolized pentamidine in pregnant healthcare workers. Chest, 106 : 1460-1462, 1994
51) Stern RS : Clinical practice. Exanthematous drug eruptions. N Engl J Med, 366 : 2492-2501, 2012
52) Delanaye P, et al : Trimethoprim, creatinine and creatinine-based equations. Nephron Clin Pract, 119 : c187-93 ; discussion c193, 2011
53) Suyama Y, et al : Safety and efficacy of upfront graded administration of trimethoprim-sulfamethoxazole in systemic lupus erythematosus : A retrospective cohort study. Mod Rheumatol, 26 : 557-561, 2016
54) Maezawa R, et al : Positivity for anti-RNP antibody is a risk factor for adverse effects caused by trimethoprim-sulfamethoxazole, a prophylactic agent for P. jiroveci pneumonia, in patients with connective tissue diseases. Mod Rheumatol, 23 : 62-70, 2013
55) Absar N, et al : Desensitization to trimethoprim/sulfamethoxazole in HIV-infected patients. J Allergy Clin Immunol, 93 : 1001-1005, 1994
56) 陶山恭博, 他 : 膠原病治療時のニューモシスチス肺炎予防に用いるST合剤によるアレルギーへの対処法は?. 週刊日本医事新報, 5020 : 50, 2020
57) 「Dubois' Lupus Erythematosus & Related Syndromes, 9th ed」 (Wallace DJ & Hahn BH/eds), 2019
58) van de Wetering MD, et al : Efficacy of oral prophylactic antibiotics in neutropenic afebrile oncology patients : a systematic review of randomised controlled trials. Eur J Cancer, 41 : 1372-1382, 2005